Cargando…

Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry

BACKGROUND: This subgroup analysis of the Cancer-VTE Registry, a nationwide, large-scale, multicenter observational study with a 1-year follow-up, assessed real-world data on venous thromboembolism (VTE) among Japanese patients with breast cancer. METHODS: Patients with stage II–IV pretreatment brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohsumi, Shozo, Watanabe, Kenichi, Kondo, Naoto, Kosaka, Yoshimasa, Ishikawa, Takashi, Kitahara, Miyuki, Kubo, Shinichiro, Oba, Mari S., Kimura, Tetsuya, Takita, Atsushi, Mukai, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284999/
https://www.ncbi.nlm.nih.gov/pubmed/37069366
http://dx.doi.org/10.1007/s12282-023-01452-7
_version_ 1785061515209998336
author Ohsumi, Shozo
Watanabe, Kenichi
Kondo, Naoto
Kosaka, Yoshimasa
Ishikawa, Takashi
Kitahara, Miyuki
Kubo, Shinichiro
Oba, Mari S.
Kimura, Tetsuya
Takita, Atsushi
Mukai, Hirofumi
author_facet Ohsumi, Shozo
Watanabe, Kenichi
Kondo, Naoto
Kosaka, Yoshimasa
Ishikawa, Takashi
Kitahara, Miyuki
Kubo, Shinichiro
Oba, Mari S.
Kimura, Tetsuya
Takita, Atsushi
Mukai, Hirofumi
author_sort Ohsumi, Shozo
collection PubMed
description BACKGROUND: This subgroup analysis of the Cancer-VTE Registry, a nationwide, large-scale, multicenter observational study with a 1-year follow-up, assessed real-world data on venous thromboembolism (VTE) among Japanese patients with breast cancer. METHODS: Patients with stage II–IV pretreatment breast cancer screened for VTE at enrollment were included. During the 1-year follow-up period, incidences of VTE, bleeding, and all-cause death, and background factors associated with VTE risk were examined. RESULTS: Of 9,630 patients in the Cancer-VTE Registry analysis set, 993 (10.3%) had breast cancer (973 [98.0%] did not have and 20 [2.0%] had VTE at baseline). The mean age was 58.4 years, 73.4% of patients had stage II cancer, and 94.8% had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0. Risk factors for VTE at baseline by univariable analysis were age ≥ 65 years, ECOG PS of 2, VTE history, and D-dimer > 1.2 μg/mL. During follow-up, the incidence of symptomatic VTE was 0.4%; incidental VTE requiring treatment, 0.1%; composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.5%; bleeding, 0.2%; cerebral infarction/transient ischemic attack/systemic embolic event, 0.2%; and all-cause death, 2.1%. One patient with symptomatic VTE developed pulmonary embolism (PE) and died. Incidences of VTE and all-cause death were higher in patients with VTE vs without VTE at baseline. CONCLUSIONS: In Japanese patients with breast cancer, VTE screening before initiating cancer treatment revealed a 2.0% prevalence of VTE. During follow-up, one patient had a fatal outcome due to PE, but the incidences of VTE were low. CLINICAL TRIAL REGISTRATION: UMIN000024942; UMIN Clinical Trials Registry: https://www.umin.ac.jp/ctr/. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12282-023-01452-7.
format Online
Article
Text
id pubmed-10284999
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-102849992023-06-23 Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry Ohsumi, Shozo Watanabe, Kenichi Kondo, Naoto Kosaka, Yoshimasa Ishikawa, Takashi Kitahara, Miyuki Kubo, Shinichiro Oba, Mari S. Kimura, Tetsuya Takita, Atsushi Mukai, Hirofumi Breast Cancer Original Article BACKGROUND: This subgroup analysis of the Cancer-VTE Registry, a nationwide, large-scale, multicenter observational study with a 1-year follow-up, assessed real-world data on venous thromboembolism (VTE) among Japanese patients with breast cancer. METHODS: Patients with stage II–IV pretreatment breast cancer screened for VTE at enrollment were included. During the 1-year follow-up period, incidences of VTE, bleeding, and all-cause death, and background factors associated with VTE risk were examined. RESULTS: Of 9,630 patients in the Cancer-VTE Registry analysis set, 993 (10.3%) had breast cancer (973 [98.0%] did not have and 20 [2.0%] had VTE at baseline). The mean age was 58.4 years, 73.4% of patients had stage II cancer, and 94.8% had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0. Risk factors for VTE at baseline by univariable analysis were age ≥ 65 years, ECOG PS of 2, VTE history, and D-dimer > 1.2 μg/mL. During follow-up, the incidence of symptomatic VTE was 0.4%; incidental VTE requiring treatment, 0.1%; composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.5%; bleeding, 0.2%; cerebral infarction/transient ischemic attack/systemic embolic event, 0.2%; and all-cause death, 2.1%. One patient with symptomatic VTE developed pulmonary embolism (PE) and died. Incidences of VTE and all-cause death were higher in patients with VTE vs without VTE at baseline. CONCLUSIONS: In Japanese patients with breast cancer, VTE screening before initiating cancer treatment revealed a 2.0% prevalence of VTE. During follow-up, one patient had a fatal outcome due to PE, but the incidences of VTE were low. CLINICAL TRIAL REGISTRATION: UMIN000024942; UMIN Clinical Trials Registry: https://www.umin.ac.jp/ctr/. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12282-023-01452-7. Springer Nature Singapore 2023-04-17 2023 /pmc/articles/PMC10284999/ /pubmed/37069366 http://dx.doi.org/10.1007/s12282-023-01452-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Ohsumi, Shozo
Watanabe, Kenichi
Kondo, Naoto
Kosaka, Yoshimasa
Ishikawa, Takashi
Kitahara, Miyuki
Kubo, Shinichiro
Oba, Mari S.
Kimura, Tetsuya
Takita, Atsushi
Mukai, Hirofumi
Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
title Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
title_full Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
title_fullStr Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
title_full_unstemmed Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
title_short Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
title_sort venous thromboembolism in japanese patients with breast cancer: subgroup analysis of the cancer-vte registry
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284999/
https://www.ncbi.nlm.nih.gov/pubmed/37069366
http://dx.doi.org/10.1007/s12282-023-01452-7
work_keys_str_mv AT ohsumishozo venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT watanabekenichi venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT kondonaoto venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT kosakayoshimasa venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT ishikawatakashi venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT kitaharamiyuki venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT kuboshinichiro venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT obamaris venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT kimuratetsuya venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT takitaatsushi venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry
AT mukaihirofumi venousthromboembolisminjapanesepatientswithbreastcancersubgroupanalysisofthecancervteregistry